Hikma Pharmaceuticals Regulatory News (HIK)

5 Apr 2007 09:50

Hikma Pharmaceuticals Plc05 April 2007 Block Listing - Six Monthly Review Name of Company: Hikma Pharmaceuticals PLC Name of scheme: Hikma Pharmaceuticals PLC 2004 Stock Option Plan Period of return: From: 10 October 2006 To: 5 April 2007 Balance under block scheme: 3,193,200 ordinary shares of 10 pence each The amount by which the block scheme has been increased, Nilif the scheme has been increased since the date of thelast return: Number of securities issued/allotted under scheme during 1,473,800 ordinary shares of 10 pence eachperiod: Balance under scheme not yet issued/allotted at end of 1,719,400 ordinary shares of 10 pence eachperiod Number and class of securities originally listed and the 166,537,951 ordinary shares of 10 pence each originallydate of admission listed on 1 November 2005 Total number of securities in issue at the end of the 169,137,407 ordinary shares of 10 pence eachperiod - ENDS - Enquiries: Hikma Pharmaceuticals PLC Henry Knowles, Company Secretary +44 20 7399 2760 Susan Ringdal, Investor Relations Director Notes to Editors About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2006, the Grouphad revenue of $317 million and profit attributable to shareholders of $54.5million. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange